Summary
- Limited evidence exists on changes in glomerular filtration rate (GFR) over time in patients with a BMI ≥35 kg/m2 treated with liraglutide 3 mg/day.
- Changes in GFR in patients with BMI ≥35 kg/m2 are related to percentage total weight loss (%TWL) and baseline GFR, regardless of diabetes presence or type of intervention (metabolic and bariatric surgery or liraglutide).
- Metabolic and bariatric surgery (MBS) and liraglutide treatment show no difference in baseline GFR or at 12 months follow-up.
- An increase of 0.32 mL/min/1.73 m2 per month of follow-up was observed in GFR.
- Factors associated with a greater increase in GFR were %TWL and baseline GFR for both interventions, independent of a history of type 2 diabetes (T2D).
Patients with severe obesity who undergo weight loss treatments such as metabolic and bariatric surgery or taking medications like liraglutide may experience changes in their kidney function. A recent study compared the effects of these two treatments on the glomerular filtration rate (GFR) in patients with a body mass index (BMI) of 35 or higher.
The study found that both metabolic and bariatric surgery and liraglutide treatment can lead to improvements in GFR over time. The rate of improvement was linked to the amount of weight lost by the patients and their baseline kidney function. Patients who lost more weight and had better kidney function at the start of treatment showed greater improvements in GFR.
The findings suggest that weight loss treatments can have positive effects on kidney function in patients with severe obesity, regardless of whether they have diabetes or which type of treatment they receive. This offers hope for individuals struggling with obesity-related health issues, highlighting the importance of maintaining a healthy weight for overall health and well-being.
Source link
Nephrology,Urology